Switching antipsychotics: Imaging the differential effect on the topography of postsynaptic density transcripts in antipsychotic-naïve vs. antipsychotic-exposed rats

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 70, Issue , 2016, Pages 24-38

  de Bartolomeis, Andrea ^a   Marmo, Federica ^a   Buonaguro, Elisabetta F ^a   Latte, Gianmarco ^a   Tomasetti, Carmine ^a   Iasevoli, Felice ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Amisulpride; Haloperidol; Homer; Treatment resistant schizophrenia

Indexed keywords

AMISULPRIDE; HALOPERIDOL; POSTSYNAPTIC DENSITY PROTEIN 95; ACTIVITY REGULATED CYTOSKELETAL-ASSOCIATED PROTEIN; CYTOSKELETON PROTEIN; DLGH4 PROTEIN, RAT; HOMER SCAFFOLDING PROTEIN; HOMER1 PROTEIN, RAT; MEMBRANE PROTEIN; MESSENGER RNA; NERVE PROTEIN; NEUROLEPTIC AGENT; SIGNAL PEPTIDE; SULPIRIDE; SULTOPRIDE;

ANIMAL EXPERIMENT; ANTERIOR CINGULATE; ARC GENE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DORSOLATERAL CAUDATE PUTAMEN; DORSOMEDIAL CAUDATE PUTAMEN; DRUG EXPOSURE; DRUG SUBSTITUTION; GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HOMER1A GENE; HOMER1B GENE; HOMER1C GENE; INSULA; MALE; MEDIAL AGRANULAR CORTEX; MOTOR CORTEX; NERVE CELL PLASTICITY; NONHUMAN; NUCLEUS ACCUMBENS; POSTSYNAPTIC DENSITY; PROTEIN INTERACTION; PROTEIN MODIFICATION; PSD 95 GENE; PUTAMEN; RAT; SOMATOSENSORY CORTEX; TREATMENT DURATION; VENTROLATERAL CAUDATE PUTAMEN; VENTROMEDIAL CAUDATE PUTAMEN; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN CORTEX; DRUG EFFECTS; DRUG RESISTANCE; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; PHYSIOLOGY; RANDOMIZATION; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; CEREBRAL CORTEX; CORPUS STRIATUM; CYTOSKELETAL PROTEINS; DRUG RESISTANCE; DRUG SUBSTITUTION; GENE EXPRESSION; HALOPERIDOL; HOMER SCAFFOLDING PROTEINS; INJECTIONS, INTRAPERITONEAL; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; NERVE TISSUE PROTEINS; POST-SYNAPTIC DENSITY; RANDOM ALLOCATION; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SULPIRIDE;

EID: 84968764115     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2016.04.015     Document Type: Article

References (66)

1. Balu D.T., Coyle J.T. Chronic d-serine reverses arc expression and partially rescues dendritic abnormalities in a mouse model of NMDA receptor hypofunction. Neurochem. Int. 2014, 75:76-78.
2. Borroto-Escuela D.O., Tarakanov A.O., Guidolin D., Ciruela F., Agnati L.F., Fuxe K. Moonlighting characteristics of G protein-coupled receptors: focus on receptor heteromers and relevance for neurodegeneration. IUBMB Life 2011, 63:463-472.
3. Bramham C.R., Worley P.F., Moore M.J., Guzowski J.F. The immediate early gene arc/arg3.1: regulation, mechanisms, and function. J. Neurosci. 2008, 28:11760-11767.
4. Cohen J.E., Lee P.R., Chen S., Li W., Fields R.D. MicroRNA regulation of homeostatic synaptic plasticity. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:11650-11655.
5. de Bartolomeis A., Iasevoli F. The Homer family and the signal transduction system at glutamatergic postsynaptic density: potential role in behavior and pharmacotherapy. Psychopharmacol. Bull. 2003, 37:51-83.
6. de Bartolomeis A., Marmo F., Buonaguro E.F., Rossi R., Tomasetti C., Iasevoli F. Imaging brain gene expression profiles by antipsychotics: region-specific action of amisulpride on postsynaptic density transcripts compared to haloperidol. Eur. Neuropsychopharmacol. 2013, 23:1516-1529.
7. de Bartolomeis A., Sarappa C., Buonaguro E.F., Marmo F., Eramo A., Tomasetti C., et al. Different effects of the NMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: role of Homer signaling, and implications for novel antipsychotic and pro-cognitive targets in psychosis. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2013, 46:1-12.
8. de Bartolomeis A., Latte G., Tomasetti C., Iasevoli F. Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches. Mol. Neurobiol. 2014, 49:484-511.
9. de Bartolomeis A., Iasevoli F., Marmo F., Buonaguro E.F., Eramo A., Rossi R., et al. Progressive recruitment of cortical and striatal regions by inducible postsynaptic density transcripts after increasing doses of antipsychotics with different receptor profiles: insights for psychosis treatment. Eur. neuropsychopharmacol. 2015, 25:566-582.
10. Dold M., Samara M.T., Li C., Tardy M., Leucht S. Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. Cochrane Database Syst. Rev. 2015, 1.
11. Fumagalli F., Frasca A., Racagni G., Riva M.A. Dynamic regulation of glutamatergic postsynaptic activity in rat prefrontal cortex by repeated administration of antipsychotic drugs. Mol. Pharmacol. 2008, 73:1484-1490.
12. Fumagalli F., Frasca A., Racagni G., Riva M.A. Antipsychotic drugs modulate Arc expression in the rat brain. Eur. Neuropsychopharmacol. 2009, 19:109-115.
13. Fuxe K., Manger P., Genedani S., Agnati L. The nigrostriatal DA pathway and Parkinson's disease. J. Neural Transm. Suppl. 2006, 71-83.
14. Gill K.M., Cook J.M., Poe M.M., Grace A.A. Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia. Schizophr. Bull. 2014, 40:341-350.
15. Grunder G., Hippius H., Carlsson A. The 'atypicality' of antipsychotics: a concept re-examined and re-defined. Nat. Rev. Drug Discov. 2009, 8:197-202.
16. Hall J., Trent S., Thomas K.L., O'Donovan M.C., Owen M.J. Genetic risk for schizophrenia: convergence on synaptic pathways involved in plasticity. Biol. Psychiatry 2014.
17. Hayashi M.K., Tang C., Verpelli C., Narayanan R., Stearns M.H., Xu R.M., et al. The postsynaptic density proteins Homer and Shank form a polymeric network structure. Cell 2009, 137:159-171.
18. Hu J.L., Liu G., Li Y.C., Gao W.J., Huang Y.Q. Dopamine D1 receptor-mediated NMDA receptor insertion depends on Fyn but not Src kinase pathway in prefrontal cortical neurons. Mol. Brain 2010, 3:20.
19. Iasevoli F., Tomasetti C., Ambesi-Impiombato A., Muscettola G., de Bartolomeis A. Dopamine receptor subtypes contribution to Homer1a induction: insights into antipsychotic molecular action. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2009, 33:813-821.
20. Iasevoli F., Fiore G., Cicale M., Muscettola G., de Bartolomeis A. Haloperidol induces higher Homer1a expression than risperidone, olanzapine and sulpiride in striatal sub-regions. Psychiatry Res. 2010, 177:255-260.
21. Iasevoli F., Tomasetti C., Marmo F., Bravi D., Arnt J., de Bartolomeis A. Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole. Psychopharmacology 2010, 212:329-344.
22. Iasevoli F., Ambesi-Impiombato A., Fiore G., Panariello F., Muscettola G., de Bartolomeis A. Pattern of acute induction of Homer1a gene is preserved after chronic treatment with first- and second-generation antipsychotics: effect of short-term drug discontinuation and comparison with Homer1a-interacting genes. J. psychopharmacol. 2011, 25:875-887.
23. Iasevoli F., Tomasetti C., de Bartolomeis A. Scaffolding proteins of the post-synaptic density contribute to synaptic plasticity by regulating receptor localization and distribution: relevance for neuropsychiatric diseases. Neurochem. Res. 2013, 38:1-22.
24. Iasevoli F., Buonaguro E.F., Sarappa C., Marmo F., Latte G., Rossi R., et al. Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: relevance to schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2014, 54:299-314.
25. Iasevoli F., Tomasetti C., Buonaguro E.F., de Bartolomeis A. The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment. Curr. Neuropharmacol. 2014, 12:219-238.
26. Kammermeier P.J. Endogenous homer proteins regulate metabotropic glutamate receptor signaling in neurons. J. Neurosci. 2008, 28:8560-8567.
27. Kapur S., Wadenberg M.L., Remington G. Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench. Can. J. Psychiatr. 2000, 45:241-246.
28. Kato T. Whole genome/exome sequencing in mood and psychotic disorders. Psychiatry Clin. Neurosci. 2015, 69:65-76.
29. Kirov G., Pocklington A.J., Holmans P., Ivanov D., Ikeda M., Ruderfer D., et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol. Psychiatry 2012, 17:142-153.
30. Krzystanek M., Bogus K., Palasz A., Krzystanek E., Worthington J.J., Wiaderkiewicz R. Effects of long-term treatment with the neuroleptics haloperidol, clozapine and olanzapine on immunoexpression of NMDA receptor subunits NR1, NR2A and NR2B in the rat hippocampus. Pharmacol. Rep. 2015, 67:965-969.
31. Kurz M., Hummer M., Oberbauer H., Fleischhacker W.W. Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology 1995, 118:52-56.
32. Leucht C., Kitzmantel M., Chua L., Kane J., Leucht S. Haloperidol versus chlorpromazine for treatment of schizophrenia. Schizophr. Bull. 2008, 34:813-815.
33. Liemburg E.J., Knegtering H., Klein H.C., Kortekaas R., Aleman A. Antipsychotic medication and prefrontal cortex activation: a review of neuroimaging findings. Eur. Neuropsychopharmacol. 2012, 22:387-400.
34. Luoni A., Fumagalli F., Racagni G., Riva M.A. Repeated aripiprazole treatment regulates Bdnf, Arc and Npas4 expression under basal condition as well as after an acute swim stress in the rat brain. Pharmacol. Res. 2014, 80:1-8.
35. Marchese G., Casu M.A., Bartholini F., Ruiu S., Saba P., Gessa G.L., et al. Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to "early onset" vacuous chewing. Eur. J. Neurosci. 2002, 15:1187-1196.
36. Meisenzahl E.M., Schmitt G., Grunder G., Dresel S., Frodl T., la Fougere C., et al. Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study. Pharmacopsychiatry 2008, 41:169-175.
37. Moller H.J. Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2001, 251:217-224.
38. Moller H.J. Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2003, 27:1101-1111.
39. Natesan S., Reckless G.E., Barlow K.B., Nobrega J.N., Kapur S. Amisulpride the 'atypical' atypical antipsychotic-comparison to haloperidol, risperidone and clozapine. Schizophr. Res. 2008, 105:224-235.
40. Nikiforuk A., Popik P. Amisulpride promotes cognitive flexibility in rats: the role of 5-HT7 receptors. Behav. Brain Res. 2013, 248:136-140.
41. Nuss P., Tessier C. Antipsychotic medication, functional outcome and quality of life in schizophrenia: focus on amisulpride. Curr. Med. Res. Opin. 2010, 26:787-801.
42. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1997, Academic Press Inc., Sidney, Australia.
43. Piccinni C., Piazza A., Poluzzi E., Tarricone I., Koci A., Berardi D., et al. Social and clinical descriptors of antipsychotic prescription. Int. J. Psychiatry Med. 2015, 49:45-62.
44. Pillai A., Terry A.V., Mahadik S.P. Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr. Res. 2006, 82:95-106.
45. Pillai A., Parikh V., Terry A.V., Mahadik S.P. Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J. Psychiatr. Res. 2007, 41:372-386.
46. Ronesi J.A., Collins K.A., Hays S.A., Tsai N.P., Guo W., Birnbaum S.G., et al. Disrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome. Nat. Neurosci. 2012, 15:431-440. (S1).
47. Sahlholm K., Zeberg H., Nilsson J., Ogren S.O., Fuxe K., Arhem P. The fast-off hypothesis revisited: a functional kinetic study of antipsychotic antagonism of the dopamine D2 receptor. Eur. Neuropsychopharmacol. 2016, 26:467-476.
48. Sala C., Piech V., Wilson N.R., Passafaro M., Liu G., Sheng M. Regulation of dendritic spine morphology and synaptic function by Shank and Homer. Neuron 2001, 31:115-130.
49. Sala C., Futai K., Yamamoto K., Worley P.F., Hayashi Y., Sheng M. Inhibition of dendritic spine morphogenesis and synaptic transmission by activity-inducible protein Homer1a. J. Neurosci. 2003, 23:6327-6337.
50. 2+ homeostasis at dendritic spines in hippocampal neurons. J Neurosci. 2005, 25:4587-4592.
51. Samaha A.N., Seeman P., Stewart J., Rajabi H., Kapur S. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J. Neurosci. 2007, 27:2979-2986.
52. Sato M., Suzuki K., Nakanishi S. NMDA receptor stimulation and brain-derived neurotrophic factor upregulate homer 1a mRNA via the mitogen-activated protein kinase cascade in cultured cerebellar granule cells. J. Neurosci. 2001, 21:3797-3805.
53. Seeman P., Ko F., Jack E., Greenstein R., Dean B. Consistent with dopamine supersensitivity, RGS9 expression is diminished in the amphetamine-treated animal model of schizophrenia and in postmortem schizophrenia brain. Synapse 2007, 61:303-309.
54. Siddoway B., Hou H., Xia H. Molecular mechanisms of homeostatic synaptic downscaling. Neuropharmacology 2014, 78:38-44.
55. Sparshatt A., Taylor D., Patel M.X., Kapur S. Amisulpride - dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring. Acta Psychiatr. Scand. 2009, 120:416-428.
56. Spellmann I., Rujescu D., Musil R., Mayr A., Giegling I., Genius J., et al. Homer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. J. Psychiatr. Res. 2011, 45:234-241.
57. Szumlinski K.K., Kalivas P.W., Worley P.F. Homer proteins: implications for neuropsychiatric disorders. Curr. Opin. Neurobiol. 2006, 16:251-257.
58. Szumlinski K.K., Ary A.W., Lominac K.D. Homers regulate drug-induced neuroplasticity: implications for addiction. Biochem. Pharmacol. 2008, 75:112-133.
59. Tomasetti C., Dell'Aversano C., Iasevoli F., de Bartolomeis A. Homer splice variants modulation within cortico-subcortical regions by dopamine D2 antagonists, a partial agonist, and an indirect agonist: implication for glutamatergic postsynaptic density in antipsychotics action. Neuroscience 2007, 150:144-158.
60. Tomasetti C., Dell'Aversano C., Iasevoli F., Marmo F., de Bartolomeis A. The acute and chronic effects of combined antipsychotic-mood stabilizing treatment on the expression of cortical and striatal postsynaptic density genes. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2011, 35:184-197.
61. Tost H., Braus D.F., Hakimi S., Ruf M., Vollmert C., Hohn F., et al. Acute D2 receptor blockade induces rapid, reversible remodeling in human cortical-striatal circuits. Nat. Neurosci. 2010, 13:920-922.
62. Turrone P., Remington G., Kapur S., Nobrega J.N. The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats. Psychopharmacology 2003, 165:166-171.
63. Varela F.A., Der-Ghazarian T., Lee R.J., Charntikov S., Crawford C.A., McDougall S.A. Repeated aripiprazole treatment causes dopamine D2 receptor up-regulation and dopamine supersensitivity in young rats. J. Psychopharmacol. 2014, 28:376-386.
64. Willuhn I., Sun W., Steiner H. Topography of cocaine-induced gene regulation in the rat striatum: relationship to cortical inputs and role of behavioural context. Eur. J. Neurosci. 2003, 17:1053-1066.
65. Wilson J.M., Ogden A.M., Loomis S., Gilmour G., Baucum A.J., Belecky-Adams T.L., et al. Phosphodiesterase 10A inhibitor, MP-10 (PF-2545920), produces greater induction of c-Fos in dopamine D2 neurons than in D1 neurons in the neostriatum. Neuropharmacology 2015, 99:379-386.
66. Yamada H., Kuroki T., Nakahara T., Hashimoto K., Tsutsumi T., Hirano M., et al. The dopamine D1 receptor agonist, but not the D2 receptor agonist, induces gene expression of Homer 1a in rat striatum and nucleus accumbens. Brain Res. 2007, 1131:88-96.